An idiopathic inflammatory myopathy characterized by proximal muscle weakness and distinctive skin manifestations including heliotrope rash and Gottron's papules. Associated with increased risk of malignancy and interstitial lung disease in certain autoantibody subsets.
Ask a research question about Dermatomyositis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Dermatomyositis
creation_date: '2025-12-19T01:12:52Z'
updated_date: '2026-04-30T12:00:00Z'
category: Autoimmune
parents:
- Autoimmune Disease
- Inflammatory Myopathy
disease_term:
preferred_term: Dermatomyositis
term:
id: MONDO:0016367
label: dermatomyositis
description: >-
An idiopathic inflammatory myopathy characterized by proximal muscle weakness
and distinctive skin manifestations including heliotrope rash and Gottron's
papules. Associated with increased risk of malignancy and interstitial lung
disease in certain autoantibody subsets.
pathophysiology:
- name: Complement-Mediated Microangiopathy
description: >-
Membrane attack complex (MAC) deposition on endomysial capillaries leads
to capillary damage, ischemia, and perifascicular atrophy characteristic
of dermatomyositis. This distinguishes it from polymyositis.
cell_types:
- preferred_term: Endothelial Cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: Complement Activation
term:
id: GO:0006956
label: complement activation
evidence:
- reference: PMID:38143369
reference_title: "Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory Myopathies."
supports: SUPPORT
snippet: >-
Deposition of complement around capillaries and/or the sarcolemma was
observed in muscle biopsy specimens from patients with DM, ASS, and IMNM,
suggesting the pathomechanism of complement-dependent muscle and endothelial
cell injury.
explanation: >-
This evidence demonstrates that complement deposition is a characteristic
pathological feature of dermatomyositis, contributing to muscle and
endothelial cell injury through complement-dependent mechanisms.
- reference: PMID:38143369
reference_title: "Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory Myopathies."
supports: SUPPORT
snippet: >-
Juvenile DM is characterized by the loss of capillaries, perivascular
inflammation, and small-vessel angiopathies, which may be related to
microinfarction and perifascicular atrophy.
explanation: >-
This evidence links the microangiopathy to the characteristic perifascicular
atrophy observed in dermatomyositis, supporting the ischemic mechanism of
muscle damage.
- name: Type I Interferon Pathway Activation
description: >-
Strong type I interferon signature in muscle and skin. Plasmacytoid
dendritic cells accumulate in affected tissues and produce IFN-alpha,
driving inflammation and MxA protein expression.
cell_types:
- preferred_term: Plasmacytoid Dendritic Cell
term:
id: CL:0000784
label: plasmacytoid dendritic cell
biological_processes:
- preferred_term: Type I Interferon Response
term:
id: GO:0034340
label: response to type I interferon
evidence:
- reference: PMID:38143369
reference_title: "Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory Myopathies."
supports: SUPPORT
snippet: >-
The pathological observation of myxovirus resistance protein A (MxA),
which suggests a type 1 interferon (IFN1) signature in DM, supports the
diagnosis and further understanding of the pathomechanism of IIM.
explanation: >-
MxA expression is a hallmark of type I interferon activation in
dermatomyositis, providing diagnostic and pathomechanistic insights.
- reference: PMID:39334579
reference_title: "Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review."
supports: SUPPORT
snippet: >-
Histopathological studies have revealed critical roles of type I interferons
and vasculopathy in the development of JDM.
explanation: >-
This evidence confirms that type I interferon signaling is a central
pathogenic mechanism in dermatomyositis, including juvenile forms.
- name: Myositis-Specific Autoantibodies
description: >-
Distinct autoantibodies define clinical phenotypes: anti-Mi-2 (classic
dermatomyositis), anti-MDA5 (amyopathic with ILD), anti-TIF1-gamma
(cancer-associated), and anti-NXP2 (calcinosis).
biological_processes:
- preferred_term: Immunoglobulin Production
term:
id: GO:0002377
label: immunoglobulin production
evidence:
- reference: PMID:39334579
reference_title: "Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review."
supports: SUPPORT
snippet: >-
Each MSA or MAA is associated with distinct clinical features and outcomes,
although there are several differences in the prevalence of MSA/MAA and
autoantibody-phenotype relationships between age and ethnic groups.
explanation: >-
This evidence confirms that myositis-specific autoantibodies (MSAs) define
distinct clinical phenotypes in dermatomyositis, supporting the concept of
autoantibody-driven disease subtypes.
- name: Perivascular Inflammation and Immune Cell Infiltration
description: >-
Perivascular inflammation contributes to muscle damage in dermatomyositis.
Immune cell infiltrates including CD4+ T cells and B cells are found in
perivascular and perimysial locations.
cell_types:
- preferred_term: CD4+ T Cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
- preferred_term: B Cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: Adaptive Immune Response
term:
id: GO:0002250
label: adaptive immune response
evidence:
- reference: PMID:38143369
supports: SUPPORT
snippet: >-
Juvenile DM is characterized by the loss of capillaries, perivascular
inflammation, and small-vessel angiopathies, which may be related to
microinfarction and perifascicular atrophy.
explanation: >-
Confirms perivascular inflammation as a characteristic feature of DM
muscle pathology.
prevalence:
- population: United States
percentage: "1.1 per 100,000 person-years (incidence); 13 per 100,000 (prevalence)"
evidence:
- reference: PMID:34549549
supports: SUPPORT
snippet: >-
The overall adjusted incidence of DM was 1.1 (95% CI 0.7-1.5) per 100,000
person-years, and prevalence was 13 (95% CI 6-19) per 100,000.
explanation: Population-based cohort study from Olmsted County using EULAR/ACR criteria.
- reference: ORPHA:221
supports: SUPPORT
snippet: "1-9 / 100 000 | United States | Annual incidence | PMID:34549549"
explanation: Orphanet epidemiology data for dermatomyositis in the United States.
- population: Norway
percentage: "8.7 per 100,000 (point prevalence)"
evidence:
- reference: PMID:24695011
supports: SUPPORT
snippet: >-
point prevalence of PM/DM was calculated to 8.7/100 000
explanation: >-
Unselected Norwegian population study identifying all PM/DM patients
in southeast Norway (denominator 2.64 million).
- reference: ORPHA:221
supports: SUPPORT
snippet: "1-9 / 100 000 | Norway | Point prevalence | PMID:24695011"
explanation: Orphanet epidemiology data for dermatomyositis in Norway.
- population: Sweden
percentage: "6-10 per 1,000,000 (annual incidence)"
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "1-9 / 1 000 000 | Sweden | Annual incidence | PMID:28160487"
explanation: Orphanet epidemiology data based on Swedish nationwide population-based study.
- population: Argentina
percentage: "1-9 per 1,000,000 (annual incidence)"
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "1-9 / 1 000 000 | Argentina | Annual incidence | PMID:23965482"
explanation: Orphanet epidemiology data for dermatomyositis in Argentina.
inheritance:
- name: Not applicable
description: >-
Dermatomyositis is an autoimmune disease, not an inherited Mendelian disorder.
HLA associations (e.g., HLA-DRB1*0301) confer genetic susceptibility but do
not follow a Mendelian pattern.
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "Not applicable"
explanation: Orphanet classifies dermatomyositis inheritance as not applicable.
phenotypes:
- name: Proximal Muscle Weakness
category: Musculoskeletal
frequency: VERY_FREQUENT
description: >-
Symmetrical proximal muscle weakness is a hallmark feature, affecting shoulder
and hip girdle muscles. Patients have difficulty rising from chairs, climbing
stairs, and lifting arms above the head.
phenotype_term:
preferred_term: Proximal muscle weakness
term:
id: HP:0003701
label: Proximal muscle weakness
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0003701 | Proximal muscle weakness | Very frequent (99-80%)"
explanation: Orphanet classifies proximal muscle weakness as very frequent (99-80%) in dermatomyositis.
- reference: PMID:37153943
supports: SUPPORT
snippet: >-
Together with skin features, patients show muscle involvement, most commonly
with symmetrical weakness of the proximal muscles.
explanation: Comprehensive review confirms symmetrical proximal muscle weakness as a core feature.
- name: Limb-Girdle Muscle Weakness
category: Musculoskeletal
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Limb-girdle muscle weakness
term:
id: HP:0003325
label: Limb-girdle muscle weakness
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0003325 | Limb-girdle muscle weakness | Very frequent (99-80%)"
explanation: Orphanet classifies limb-girdle weakness as very frequent in dermatomyositis.
- name: Myalgia
category: Musculoskeletal
frequency: VERY_FREQUENT
description: Muscle pain is a very frequent symptom, reported in up to 75% of patients.
phenotype_term:
preferred_term: Myalgia
term:
id: HP:0003326
label: Myalgia
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0003326 | Myalgia | Very frequent (99-80%)"
explanation: Orphanet classifies myalgia as very frequent in dermatomyositis.
- reference: PMID:24695011
supports: SUPPORT
snippet: >-
Frequent clinical features included myalgia (75%), arthritis (41%)
dyspnoea (62%) and dysphagia (58%).
explanation: Norwegian population-based cohort found myalgia in 75% of PM/DM patients.
- name: Hypotonia
category: Musculoskeletal
frequency: FREQUENT
phenotype_term:
preferred_term: Hypotonia
term:
id: HP:0001252
label: Hypotonia
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001252 | Hypotonia | Frequent (79-30%)"
explanation: Orphanet classifies hypotonia as frequent in dermatomyositis.
- name: Inflammatory Myopathy
category: Musculoskeletal
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Inflammatory myopathy
term:
id: HP:0009071
label: Inflammatory myopathy
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0009071 | Inflammatory myopathy | Very frequent (99-80%)"
explanation: Orphanet classifies inflammatory myopathy as very frequent in dermatomyositis.
- name: Heliotrope Rash
category: Dermatological
frequency: FREQUENT
description: >-
Violaceous discoloration of the eyelids, often with periorbital edema.
A pathognomonic cutaneous finding of dermatomyositis.
phenotype_term:
preferred_term: Heliotrope rash
term:
id: HP:0040324
label: Heliotrope rash
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0040324 | Heliotrope rash | Frequent (79-30%)"
explanation: Orphanet classifies heliotrope rash as frequent in dermatomyositis.
- reference: PMID:37153943
supports: SUPPORT
snippet: >-
heliotrope rash, and violaceous papules located at the interphalangeal or
metacarpophalangeal joints (Gottron's papules) are the most frequently observed.
explanation: Comprehensive review identifies heliotrope rash as one of the most frequent skin findings.
- name: Gottron's Papules
category: Dermatological
frequency: FREQUENT
description: >-
Violaceous papules over the dorsal interphalangeal and metacarpophalangeal
joints. A pathognomonic cutaneous finding of dermatomyositis.
phenotype_term:
preferred_term: Gottron's papules
term:
id: HP:0025508
label: Gottron's papules
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0025508 | Gottron's papules | Frequent (79-30%)"
explanation: Orphanet classifies Gottron's papules as frequent in dermatomyositis.
- reference: PMID:37153943
supports: SUPPORT
snippet: >-
heliotrope rash, and violaceous papules located at the interphalangeal or
metacarpophalangeal joints (Gottron's papules) are the most frequently observed.
explanation: Comprehensive review identifies Gottron's papules as one of the most frequent skin findings.
- name: Gottron Sign
category: Dermatological
frequency: OCCASIONAL
description: >-
Erythematous or violaceous macules over the extensor surfaces of joints,
distinct from the raised papules of Gottron's papules.
phenotype_term:
preferred_term: Gottron sign
term:
id: HP:0430033
label: Gottron sign
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0430033 | Gottron sign | Occasional (29-5%)"
explanation: Orphanet classifies Gottron sign as occasional in dermatomyositis.
- name: Periorbital Edema
category: Dermatological
frequency: VERY_FREQUENT
description: >-
Edema around the eyes, often accompanying heliotrope rash. A characteristic
early finding.
phenotype_term:
preferred_term: Periorbital edema
term:
id: HP:0100539
label: Periorbital edema
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0100539 | Periorbital edema | Very frequent (99-80%)"
explanation: Orphanet classifies periorbital edema as very frequent in dermatomyositis.
- name: Erythema
category: Dermatological
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Erythema
term:
id: HP:0010783
label: Erythema
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0010783 | Erythema | Very frequent (99-80%)"
explanation: Orphanet classifies erythema as very frequent in dermatomyositis.
- name: Facial Erythema
category: Dermatological
frequency: FREQUENT
phenotype_term:
preferred_term: Facial erythema
term:
id: HP:0001041
label: Facial erythema
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001041 | Facial erythema | Frequent (79-30%)"
explanation: Orphanet classifies facial erythema as frequent in dermatomyositis.
- name: V-Sign
category: Dermatological
frequency: OCCASIONAL
description: >-
Erythematous rash over the anterior chest and neck in a V-shaped distribution.
phenotype_term:
preferred_term: V-sign
term:
id: HP:0025536
label: V-sign
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0025536 | V-sign | Occasional (29-5%)"
explanation: Orphanet classifies V-sign as occasional in dermatomyositis.
- name: Shawl Sign
category: Dermatological
frequency: FREQUENT
description: >-
Erythematous rash over the upper back, posterior shoulders, and upper arms
in a shawl-like distribution.
phenotype_term:
preferred_term: Shawl sign
term:
id: HP:0025535
label: Shawl sign
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0025535 | Shawl sign | Frequent (79-30%)"
explanation: Orphanet classifies shawl sign as frequent in dermatomyositis.
- name: Holster Sign
category: Dermatological
frequency: OCCASIONAL
description: >-
Erythematous rash over the lateral thighs, resembling a gun holster distribution.
phenotype_term:
preferred_term: Holster sign
term:
id: HP:6000006
label: Holster sign
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:6000006 | Holster sign | Occasional (29-5%)"
explanation: Orphanet classifies holster sign as occasional in dermatomyositis.
- name: Cutaneous Photosensitivity
category: Dermatological
frequency: OCCASIONAL
phenotype_term:
preferred_term: Cutaneous photosensitivity
term:
id: HP:0000992
label: Cutaneous photosensitivity
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0000992 | Cutaneous photosensitivity | Occasional (29-5%)"
explanation: Orphanet classifies cutaneous photosensitivity as occasional in dermatomyositis.
- name: Skin Ulcer
category: Dermatological
frequency: FREQUENT
description: >-
Cutaneous ulceration is associated with increased cancer risk in dermatomyositis.
phenotype_term:
preferred_term: Skin ulcer
term:
id: HP:0200042
label: Skin ulcer
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0200042 | Skin ulcer | Frequent (79-30%)"
explanation: Orphanet classifies skin ulcer as frequent in dermatomyositis.
- reference: PMID:33599244
supports: SUPPORT
snippet: >-
cutaneous ulceration (RR 2.73)
explanation: >-
Meta-analysis identifies cutaneous ulceration as a significant risk factor
for cancer in IIM (risk ratio 2.73).
- name: Pruritus
category: Dermatological
frequency: FREQUENT
phenotype_term:
preferred_term: Pruritus
term:
id: HP:0000989
label: Pruritus
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0000989 | Pruritus | Frequent (79-30%)"
explanation: Orphanet classifies pruritus as frequent in dermatomyositis.
- name: Poikiloderma
category: Dermatological
frequency: OCCASIONAL
phenotype_term:
preferred_term: Poikiloderma
term:
id: HP:0001029
label: Poikiloderma
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001029 | Poikiloderma | Occasional (29-5%)"
explanation: Orphanet classifies poikiloderma as occasional in dermatomyositis.
- name: Acrocyanosis
category: Dermatological
frequency: FREQUENT
phenotype_term:
preferred_term: Acrocyanosis
term:
id: HP:0001063
label: Acrocyanosis
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001063 | Acrocyanosis | Frequent (79-30%)"
explanation: Orphanet classifies acrocyanosis as frequent in dermatomyositis.
- name: Raynaud Phenomenon
category: Dermatological
frequency: OCCASIONAL
description: >-
Episodic vasospasm of the fingers and toes. Associated with reduced cancer
risk in DM (protective factor).
phenotype_term:
preferred_term: Raynaud phenomenon
term:
id: HP:0030880
label: Raynaud phenomenon
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0030880 | Raynaud phenomenon | Occasional (29-5%)"
explanation: Orphanet classifies Raynaud phenomenon as occasional in dermatomyositis.
- reference: PMID:33599244
supports: SUPPORT
snippet: >-
Raynaud's phenomenon (RR 0.61)
explanation: >-
Meta-analysis shows Raynaud phenomenon is associated with reduced cancer
risk in IIM (protective factor, RR 0.61).
- name: Pulmonary Fibrosis
category: Respiratory
frequency: FREQUENT
description: >-
Interstitial lung disease is a major complication, especially with anti-MDA5
antibodies. Rapidly progressive ILD is a leading cause of mortality.
phenotype_term:
preferred_term: Pulmonary fibrosis
term:
id: HP:0002206
label: Pulmonary fibrosis
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002206 | Pulmonary fibrosis | Frequent (79-30%)"
explanation: Orphanet classifies pulmonary fibrosis as frequent in dermatomyositis.
- reference: PMID:38456909
supports: SUPPORT
snippet: >-
Anti-melanoma differentiation-associated protein 5 antibody-positive
dermatomyositis (anti-MDA5-DM) is frequently complicated by progressive
interstitial lung disease (ILD), the prognosis of which is poor, and
management is a major challenge.
explanation: >-
Anti-MDA5 positive dermatomyositis is strongly associated with progressive ILD.
- reference: PMID:39334579
supports: SUPPORT
snippet: >-
However, rapidly progressive interstitial lung disease (RP-ILD) remains a
major cause of death in anti-melanoma differentiation gene 5 autoantibody-positive
JDM.
explanation: RP-ILD is a leading cause of death in anti-MDA5 positive DM.
- name: Respiratory Insufficiency
category: Respiratory
frequency: FREQUENT
phenotype_term:
preferred_term: Respiratory insufficiency
term:
id: HP:0002093
label: Respiratory insufficiency
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002093 | Respiratory insufficiency | Frequent (79-30%)"
explanation: Orphanet classifies respiratory insufficiency as frequent in dermatomyositis.
- name: Respiratory Insufficiency due to Muscle Weakness
category: Respiratory
frequency: FREQUENT
description: >-
Weakness of respiratory muscles (diaphragm and intercostals) contributing
to ventilatory failure.
phenotype_term:
preferred_term: Respiratory insufficiency due to muscle weakness
term:
id: HP:0002747
label: Respiratory insufficiency due to muscle weakness
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002747 | Respiratory insufficiency due to muscle weakness | Frequent (79-30%)"
explanation: Orphanet classifies respiratory muscle weakness as frequent in dermatomyositis.
- reference: PMID:24695011
supports: SUPPORT
snippet: >-
Frequent clinical features included myalgia (75%), arthritis (41%)
dyspnoea (62%) and dysphagia (58%).
explanation: Norwegian cohort found dyspnoea in 62% of PM/DM patients.
- name: Dysphagia
category: Gastrointestinal
frequency: OCCASIONAL
description: >-
Pharyngeal and esophageal muscle involvement leads to swallowing difficulty.
Associated with increased cancer risk (RR 2.09).
phenotype_term:
preferred_term: Dysphagia
term:
id: HP:0002015
label: Dysphagia
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002015 | Dysphagia | Occasional (29-5%)"
explanation: >-
Orphanet classifies dysphagia as occasional in dermatomyositis. Note that
frequency estimates vary; the Norwegian cohort found 58%.
- reference: PMID:24695011
supports: SUPPORT
snippet: >-
Frequent clinical features included myalgia (75%), arthritis (41%)
dyspnoea (62%) and dysphagia (58%).
explanation: Norwegian population study found dysphagia in 58% of PM/DM patients.
- reference: PMID:33599244
supports: SUPPORT
snippet: >-
dysphagia (RR 2.09)
explanation: >-
Meta-analysis identifies dysphagia as a significant cancer risk factor
in IIM (RR 2.09).
- name: Dysphonia
category: Neurological
frequency: OCCASIONAL
phenotype_term:
preferred_term: Dysphonia
term:
id: HP:0001618
label: Dysphonia
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001618 | Dysphonia | Occasional (29-5%)"
explanation: Orphanet classifies dysphonia as occasional in dermatomyositis.
- name: Arthralgia
category: Musculoskeletal
frequency: FREQUENT
description: Joint pain, commonly affecting the small joints of the hands.
phenotype_term:
preferred_term: Arthralgia
term:
id: HP:0002829
label: Arthralgia
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002829 | Arthralgia | Frequent (79-30%)"
explanation: Orphanet classifies arthralgia as frequent in dermatomyositis.
- name: Arthritis
category: Musculoskeletal
frequency: FREQUENT
phenotype_term:
preferred_term: Arthritis
term:
id: HP:0001369
label: Arthritis
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001369 | Arthritis | Frequent (79-30%)"
explanation: Orphanet classifies arthritis as frequent in dermatomyositis.
- reference: PMID:24695011
supports: SUPPORT
snippet: >-
Frequent clinical features included myalgia (75%), arthritis (41%)
dyspnoea (62%) and dysphagia (58%).
explanation: Norwegian cohort found arthritis in 41% of PM/DM patients.
- name: Fatigue
category: Constitutional
frequency: FREQUENT
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0012378 | Fatigue | Frequent (79-30%)"
explanation: Orphanet classifies fatigue as frequent in dermatomyositis.
- name: Weight Loss
category: Constitutional
frequency: FREQUENT
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001824 | Weight loss | Frequent (79-30%)"
explanation: Orphanet classifies weight loss as frequent in dermatomyositis.
- name: Fever
category: Constitutional
frequency: OCCASIONAL
phenotype_term:
preferred_term: Fever
term:
id: HP:0001945
label: Fever
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001945 | Fever | Occasional (29-5%)"
explanation: Orphanet classifies fever as occasional in dermatomyositis.
- name: Malignancy
category: Oncological
frequency: OCCASIONAL
description: >-
Around one in four IIM patients are diagnosed with cancer within 3 years of
onset. Risk factors include DM subtype, older age, male sex, dysphagia,
cutaneous ulceration, and anti-TIF1-gamma positivity.
phenotype_term:
preferred_term: Neoplasm
term:
id: HP:0002664
label: Neoplasm
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002664 | Neoplasm | Occasional (29-5%)"
explanation: Orphanet classifies neoplasm as occasional in dermatomyositis.
- reference: PMID:33599244
supports: SUPPORT
snippet: >-
DM subtype (RR 2.21), older age (WMD 11.19), male sex (RR 1.53), dysphagia
(RR 2.09), cutaneous ulceration (RR 2.73) and anti-transcriptional
intermediary factor-1 gamma positivity (RR 4.66) were identified as being
associated with significantly increased risk of cancer.
explanation: >-
Systematic review and meta-analysis of 69 studies identifies key cancer
risk factors in IIM, with DM subtype itself conferring a 2.21-fold
increased risk.
- reference: PMID:33599244
supports: SUPPORT
snippet: >-
Around one in four patients are diagnosed with cancer within 3 years before
or after IIM onset
explanation: Approximately 25% of IIM patients develop cancer temporally related to disease onset.
- name: Myocarditis
category: Cardiovascular
frequency: OCCASIONAL
phenotype_term:
preferred_term: Myocarditis
term:
id: HP:0012819
label: Myocarditis
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0012819 | Myocarditis | Occasional (29-5%)"
explanation: Orphanet classifies myocarditis as occasional in dermatomyositis.
- name: Pericarditis
category: Cardiovascular
frequency: OCCASIONAL
phenotype_term:
preferred_term: Pericarditis
term:
id: HP:0001701
label: Pericarditis
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001701 | Pericarditis | Occasional (29-5%)"
explanation: Orphanet classifies pericarditis as occasional in dermatomyositis.
- name: Arrhythmia
category: Cardiovascular
frequency: OCCASIONAL
phenotype_term:
preferred_term: Arrhythmia
term:
id: HP:0011675
label: Arrhythmia
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0011675 | Arrhythmia | Occasional (29-5%)"
explanation: Orphanet classifies arrhythmia as occasional in dermatomyositis.
- name: Vasculitis
category: Cardiovascular
frequency: OCCASIONAL
phenotype_term:
preferred_term: Vasculitis
term:
id: HP:0002633
label: Vasculitis
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002633 | Vasculitis | Occasional (29-5%)"
explanation: Orphanet classifies vasculitis as occasional in dermatomyositis.
- name: Elevated Creatine Kinase
category: Laboratory
frequency: FREQUENT
phenotype_term:
preferred_term: Elevated circulating creatine kinase concentration
term:
id: HP:0003236
label: Elevated circulating creatine kinase concentration
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0003236 | Elevated circulating creatine kinase concentration | Frequent (79-30%)"
explanation: Orphanet classifies elevated CK as frequent in dermatomyositis.
- name: Elevated Aldolase
category: Laboratory
frequency: FREQUENT
phenotype_term:
preferred_term: Elevated circulating aldolase concentration
term:
id: HP:0012544
label: Elevated circulating aldolase concentration
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0012544 | Elevated circulating aldolase concentration | Frequent (79-30%)"
explanation: Orphanet classifies elevated aldolase as frequent in dermatomyositis.
- name: Elevated LDH
category: Laboratory
frequency: FREQUENT
phenotype_term:
preferred_term: Increased circulating lactate dehydrogenase concentration
term:
id: HP:0025435
label: Increased circulating lactate dehydrogenase concentration
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0025435 | Increased circulating lactate dehydrogenase concentration | Frequent (79-30%)"
explanation: Orphanet classifies elevated LDH as frequent in dermatomyositis.
- name: Elevated Hepatic Transaminases
category: Laboratory
frequency: FREQUENT
phenotype_term:
preferred_term: Elevated circulating hepatic transaminase concentration
term:
id: HP:0002910
label: Elevated circulating hepatic transaminase concentration
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002910 | Elevated circulating hepatic transaminase concentration | Frequent (79-30%)"
explanation: Orphanet classifies elevated transaminases as frequent in dermatomyositis.
- name: Calcinosis Cutis
category: Dermatological
frequency: FREQUENT
description: >-
Dystrophic calcinosis cutis, deposition of calcium in soft tissues and
subcutaneous tissue. More common in juvenile DM and anti-NXP2 positive patients.
phenotype_term:
preferred_term: Calcinosis cutis
term:
id: HP:0025520
label: Calcinosis cutis
notes: >-
Orphanet maps this as HP:0000934 Chondrocalcinosis; HP:0025520 Calcinosis
cutis is the more precise term for DM-associated dystrophic calcification.
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0000934 | Chondrocalcinosis | Frequent (79-30%)"
explanation: >-
Orphanet classifies this as chondrocalcinosis (frequent). The more precise
HP term for DM-associated calcinosis is HP:0025520 Calcinosis cutis.
- reference: PMID:38929957
supports: SUPPORT
snippet: >-
A total of 839 CTD patients were identified, of whom 56 had calcinosis
(6.67%).
explanation: >-
Retrospective study confirms calcinosis prevalence of 6.67% across
autoimmune connective tissue diseases including dermatomyositis.
- name: EMG Abnormality
category: Diagnostic
frequency: VERY_FREQUENT
description: >-
Electromyographic findings include spontaneous fibrillation, complex
repetitive discharges, and short-duration low-amplitude polyphasic motor
unit potentials. A core diagnostic criterion for DM.
phenotype_term:
preferred_term: EMG abnormality
term:
id: HP:0003457
label: EMG abnormality
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0003457 | EMG abnormality | Very frequent (99-80%)"
explanation: Orphanet classifies EMG abnormality as very frequent in dermatomyositis.
- name: Abnormal Nail Morphology
category: Dermatological
frequency: FREQUENT
description: >-
Nailfold capillary changes including dilated capillary loops, dropout, and
bushy capillaries are hallmarks of DM microangiopathy.
phenotype_term:
preferred_term: Abnormal nail morphology
term:
id: HP:0001597
label: Abnormal nail morphology
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0001597 | Abnormality of the nail | Frequent (79-30%)"
explanation: Orphanet classifies nail abnormalities as frequent in dermatomyositis.
- name: Recurrent Respiratory Infections
category: Respiratory
frequency: FREQUENT
phenotype_term:
preferred_term: Recurrent respiratory infections
term:
id: HP:0002205
label: Recurrent respiratory infections
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002205 | Recurrent respiratory infections | Frequent (79-30%)"
explanation: Orphanet classifies recurrent respiratory infections as frequent in dermatomyositis.
- name: Diffuse Reticular or Finely Nodular Infiltrations
category: Respiratory
frequency: FREQUENT
phenotype_term:
preferred_term: Diffuse reticular or finely nodular infiltrations
term:
id: HP:0002207
label: Diffuse reticular or finely nodular infiltrations
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0002207 | Diffuse reticular or finely nodular infiltrations | Frequent (79-30%)"
explanation: Orphanet classifies diffuse reticular infiltrations as frequent in dermatomyositis.
- name: Abnormal Pulmonary Interstitial Morphology
category: Respiratory
frequency: FREQUENT
phenotype_term:
preferred_term: Abnormal pulmonary interstitial morphology
term:
id: HP:0006530
label: Abnormal pulmonary interstitial morphology
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0006530 | Abnormal pulmonary interstitial morphology | Frequent (79-30%)"
explanation: Orphanet classifies abnormal pulmonary interstitial morphology as frequent in dermatomyositis.
- name: Dry Skin
category: Dermatological
frequency: FREQUENT
phenotype_term:
preferred_term: Dry skin
term:
id: HP:0000958
label: Dry skin
evidence:
- reference: ORPHA:221
supports: SUPPORT
snippet: "HP:0000958 | Dry skin | Frequent (79-30%)"
explanation: Orphanet classifies dry skin as frequent in dermatomyositis.
biochemical:
- name: Creatine Kinase
presence: Elevated
context: Marker of muscle damage
- name: Aldolase
presence: Elevated
context: Muscle enzyme
- name: Anti-Mi-2 Antibodies
presence: Variable
context: Classic DM, good prognosis
- name: Anti-MDA5 Antibodies
presence: Variable
context: Amyopathic DM with ILD risk
genetic:
- name: HLA-DRB1*0301
association: Risk Factor
notes: >-
HLA class II allele conferring genetic susceptibility to dermatomyositis.
- name: TRIM33 (TIF1-gamma)
gene_term:
preferred_term: TRIM33
term:
id: hgnc:16290
label: TRIM33
association: Associated
notes: >-
Autoantigen target of anti-TIF1-gamma antibodies. Anti-TIF1-gamma positivity
is associated with cancer-associated dermatomyositis (RR 4.66 for malignancy).
evidence:
- reference: PMID:31279808
supports: SUPPORT
snippet: >-
anti-Mi2, -MDA5, -NXP2, -TIF1, and -SAE antibodies may be correlated with
distinct DM subtypes in terms of cutaneous manifestations, systemic involvement,
and malignancy risk.
explanation: >-
Review confirms anti-TIF1 (TRIM33) antibodies define a DM subtype with
distinct clinical features and cancer risk.
- name: IFIH1 (MDA5)
gene_term:
preferred_term: IFIH1
term:
id: hgnc:18873
label: IFIH1
association: Associated
notes: >-
Autoantigen target of anti-MDA5 antibodies. Anti-MDA5 positivity defines
clinically amyopathic DM with high risk of rapidly progressive ILD.
evidence:
- reference: PMID:31279808
supports: SUPPORT
snippet: >-
anti-Mi2, -MDA5, -NXP2, -TIF1, and -SAE antibodies may be correlated with
distinct DM subtypes in terms of cutaneous manifestations, systemic involvement,
and malignancy risk.
explanation: >-
Review confirms anti-MDA5 (IFIH1) antibodies define a DM subtype with
amyopathic presentation and ILD risk.
- name: CHD4 (Mi-2)
gene_term:
preferred_term: CHD4
term:
id: hgnc:1919
label: CHD4
association: Associated
notes: >-
Autoantigen target of anti-Mi-2 antibodies. Anti-Mi-2 positivity defines
classic dermatomyositis with good prognosis and strong skin involvement.
evidence:
- reference: PMID:31279808
supports: SUPPORT
snippet: >-
anti-Mi2, -MDA5, -NXP2, -TIF1, and -SAE antibodies may be correlated with
distinct DM subtypes in terms of cutaneous manifestations, systemic involvement,
and malignancy risk.
explanation: >-
Review confirms anti-Mi-2 (CHD4) antibodies define classic DM with
good prognosis.
- name: MORC3 (NXP-2)
gene_term:
preferred_term: MORC3
term:
id: hgnc:23572
label: MORC3
association: Associated
notes: >-
Autoantigen target of anti-NXP2 antibodies. Anti-NXP2 positivity is
associated with calcinosis and cancer risk.
evidence:
- reference: PMID:31279808
supports: SUPPORT
snippet: >-
anti-Mi2, -MDA5, -NXP2, -TIF1, and -SAE antibodies may be correlated with
distinct DM subtypes in terms of cutaneous manifestations, systemic involvement,
and malignancy risk.
explanation: >-
Review confirms anti-NXP2 (MORC3) antibodies define a DM subtype with
distinct clinical features.
- name: SAE1 (SAE)
gene_term:
preferred_term: SAE1
term:
id: hgnc:30660
label: SAE1
association: Associated
notes: >-
Autoantigen target of anti-SAE antibodies. Anti-SAE positivity defines a
subtype with initial skin-predominant disease that later develops myopathy.
evidence:
- reference: PMID:31279808
supports: SUPPORT
snippet: >-
anti-Mi2, -MDA5, -NXP2, -TIF1, and -SAE antibodies may be correlated with
distinct DM subtypes in terms of cutaneous manifestations, systemic involvement,
and malignancy risk.
explanation: >-
Review confirms anti-SAE (SAE1) antibodies define a DM subtype with
skin-predominant presentation.
treatments:
- name: Corticosteroids
description: First-line therapy for muscle and skin inflammation.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: prednisolone
term:
id: CHEBI:8378
label: prednisolone
- name: Methotrexate
description: Steroid-sparing immunosuppressant.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: methotrexate
term:
id: CHEBI:44185
label: methotrexate
- name: Azathioprine
description: Steroid-sparing immunosuppressant for maintenance therapy.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: azathioprine
term:
id: CHEBI:2948
label: azathioprine
evidence:
- reference: PMID:37153943
supports: SUPPORT
snippet: >-
several steroid-sparing agents, such as methotrexate, azathioprine or
mycophenolate mofetil, have been reported as effective in treating DM.
explanation: Comprehensive review confirms azathioprine as an effective steroid-sparing agent.
- name: Mycophenolate Mofetil
description: Steroid-sparing immunosuppressant.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: mycophenolate mofetil
term:
id: CHEBI:8764
label: mycophenolate mofetil
evidence:
- reference: PMID:37153943
supports: SUPPORT
snippet: >-
several steroid-sparing agents, such as methotrexate, azathioprine or
mycophenolate mofetil, have been reported as effective in treating DM.
explanation: Comprehensive review confirms mycophenolate mofetil as an effective steroid-sparing agent.
- name: Hydroxychloroquine
description: Antimalarial agent used for cutaneous disease manifestations.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: hydroxychloroquine
term:
id: CHEBI:5801
label: hydroxychloroquine
- name: IVIG
description: >-
Intravenous immunoglobulin for refractory disease, especially skin
manifestations. Modulates complement-mediated pathways.
treatment_term:
preferred_term: immunotherapy
term:
id: MAXO:0001002
label: immunotherapy procedure
- name: Rituximab
description: Anti-CD20 monoclonal antibody for refractory myositis.
treatment_term:
preferred_term: immunotherapy
term:
id: MAXO:0001002
label: immunotherapy procedure
therapeutic_agent:
- preferred_term: rituximab
term:
id: NCIT:C1702
label: Rituximab
evidence:
- reference: PMID:39334579
reference_title: "Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment and Interstitial Lung Diseases-A Narrative Review."
supports: PARTIAL
snippet: >-
Rituximab and JAKi may reduce mortality in patients with JDM-associated
RP-ILD refractory to conventional therapy.
explanation: >-
This evidence supports the use of rituximab in severe, refractory cases,
particularly those with rapidly progressive interstitial lung disease.
- name: JAK Inhibitors
description: >-
Emerging therapy targeting type I interferon pathway. Tofacitinib, baricitinib,
and ruxolitinib show efficacy in refractory cutaneous disease and anti-MDA5
associated ILD.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: tofacitinib
term:
id: CHEBI:71200
label: tofacitinib
evidence:
- reference: PMID:38576610
reference_title: "Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis/dermatomyositis: a single-arm systemic meta-analysis."
supports: SUPPORT
snippet: >-
Regarding skin lesions, the CDASI decreased by 17.67 (95% CI: -20.94 ~ -14.41).
explanation: >-
This meta-analysis demonstrates significant improvement in skin disease
severity (measured by CDASI) with JAK inhibitor therapy in dermatomyositis
patients.
- reference: PMID:38456909
reference_title: "Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease."
supports: PARTIAL
snippet: >-
We treated three patients with anti-MDA5-DM-associated ILD (anti-MDA5-DM-ILD)
using the Janus kinase (JAK) inhibitor, baricitinib, which improved lung
opacities and saved two patients.
explanation: >-
This case series provides evidence for the efficacy of baricitinib in
treating severe anti-MDA5 associated interstitial lung disease.
- reference: PMID:38456909
reference_title: "Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease."
supports: PARTIAL
snippet: >-
All patients except one were treated with tofacitinib, and the survival
rate was 75.9%.
explanation: >-
This systematic review demonstrates a 75.9% survival rate in anti-MDA5
positive dermatomyositis-ILD treated with JAK inhibitors, supporting their
use in this life-threatening complication.
classifications:
harrisons_chapter:
- classification_value: musculoskeletal system disorder
- classification_value: connective tissue disease
- classification_value: autoimmune disease
references:
- reference: DOI:10.1007/s00281-025-01054-9
title: 'Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms
and their implications for treatment'
findings: []
- reference: DOI:10.1007/s00296-024-05551-2
title: 'Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive
dermatomyositis-associated interstitial lung disease: a case series and literature
review on Janus kinase inhibitors for the disease'
findings: []
- reference: DOI:10.1007/s11926-024-01164-7
title: Recent Updates on the Pathogenesis of Inflammatory Myopathies
findings: []
- reference: DOI:10.1007/s40272-024-00658-2
title: 'Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current
Treatment, and Emerging Targeted Therapies'
findings: []
- reference: DOI:10.1080/14656566.2024.2392021
title: Current evidence for janus kinase inhibitors in adult and juvenile
dermatomyositis and key comparisons
findings: []
- reference: DOI:10.1080/1744666x.2024.2312819
title: Updates on efficacy and safety janus kinase inhibitors in juvenile
dermatomyositis
findings: []
- reference: DOI:10.3233/jnd-230168
title: Contribution of Complement, Microangiopathy and Inflammation in
Idiopathic Inflammatory Myopathies
findings: []
- reference: DOI:10.3389/fimmu.2023.1151695
title: Type I interferon score is associated with the severity and poor
prognosis in anti-MDA5 antibody-positive dermatomyositis patients
findings: []
- reference: DOI:10.3389/fimmu.2024.1382728
title: 'Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis/dermatomyositis:
a single-arm systemic meta-analysis'
findings: []
- reference: DOI:10.3389/fmed.2023.1158768
title: 'Targeting intracellular pathways in idiopathic inflammatory myopathies:
A narrative review'
findings: []
- reference: DOI:10.3390/children11091046
title: 'Advances in Juvenile Dermatomyositis: Pathophysiology, Diagnosis, Treatment
and Interstitial Lung Diseases—A Narrative Review'
findings: []
- reference: DOI:10.55563/clinexprheumatol/eeglsa
title: 'Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and
clinical rationale for dermatomyositis'
findings: []
- reference: DOI:10.7759/cureus.88601
title: 'Dermatomyositis: A Narrative Review of Skin as a Window to Muscle and Malignancy'
findings: []
Disease Pathophysiology Research Report
Target Disease - Disease Name: Dermatomyositis (DM) - MONDO ID: MONDO:0005377 - Category: Autoimmune
Pathophysiology description Dermatomyositis is a systemic autoimmune microangiopathy of skin, skeletal muscle, and frequently lung, characterized by complement-mediated capillary injury, a dominant type I interferon (IFN-I) transcriptional signature, and serologically defined subtypes driven by myositis-specific autoantibodies (MSAs). Histopathology demonstrates endothelial and myofiber damage with perifascicular atrophy, perivascular/perifascicular inflammatory infiltrates enriched for CD4+ T cells and plasmacytoid dendritic cells (pDCs), and membrane attack complex (MAC; C5b-9) deposition on endomysial capillaries and the sarcolemma, linking complement activation to microvascular ischemia and tissue injury (publication: Journal of Neuromuscular Diseases, Dec 2024; https://doi.org/10.3233/jnd-230168; and supportive review) (honda2024contributionofcomplement pages 1-3, honda2024contributionofcomplement pages 8-10, cristofori2025dermatomyositisanarrative pages 2-3).
A pervasive IFN-I signature marked by MxA/ISG expression is observed in blood, skin, endothelium, and muscle, and correlates with disease activity; pDCs are present in inflamed tissue and are likely major local sources of IFN-I (publications: Current Rheumatology Reports, Sep 2024, https://doi.org/10.1007/s11926-024-01164-7; Children, Aug 2024, https://doi.org/10.3390/children11091046) (musai2024recentupdateson pages 1-2, kobayashi2024advancesinjuvenile pages 13-14). MSAs define phenotypes and risks: anti-TIF1-γ (TRIM33) and anti-NXP2 associate with malignancy; anti-MDA5 (IFIH1) correlates with clinically amyopathic presentations and high risk of rapidly progressive interstitial lung disease (RP-ILD); anti-Mi-2 (CHD4) is linked to classic cutaneous disease and favorable prognosis; anti-SAE often presents with florid skin disease and delayed weakness (publications and narrative reviews with URLs: Curr Rheumatol Rep 2024, https://doi.org/10.1007/s11926-024-01164-7; Cureus, Jul 2025, https://doi.org/10.7759/cureus.88601; Seminars in Immunopathology, Aug 2025, https://doi.org/10.1007/s00281-025-01054-9) (musai2024recentupdateson pages 1-2, cristofori2025dermatomyositisanarrative pages 3-4, ali2025dermatomyositisfocuson pages 1-2, cristofori2025dermatomyositisanarrative pages 2-3).
Therapeutically, the IFN–JAK/STAT axis is targetable: JAK inhibitors (tofacitinib, baricitinib, ruxolitinib; and selective TYK2/JAK1 inhibitor brepocitinib) have shown improvements in refractory cutaneous and systemic disease, including RP-ILD, with emerging safety considerations such as opportunistic infections (publication dates and URLs: Frontiers in Immunology, Mar 2024, https://doi.org/10.3389/fimmu.2024.1382728; Rheumatology International, Mar 2024, https://doi.org/10.1007/s00296-024-05551-2; Expert Opin Pharmacother, Aug 2024, https://doi.org/10.1080/14656566.2024.2392021; Clin Exp Rheumatology, Mar 2025, https://doi.org/10.55563/clinexprheumatol/eeglsa) (ma2024therapeuticefficacyand pages 1-2, harada2024baricitinibforantimelanoma pages 7-8, wallwork2024currentevidencefor pages 1-3, paik2025brepocitinibapotent pages 1-2).
1) Core Pathophysiology - Primary mechanisms: immune-mediated microangiopathy with complement MAC (C5b-9) deposition injuring endomysial capillaries and myofibers; ischemia produces perifascicular atrophy. Concurrent IFN-I–dominated innate immune activation amplifies endothelial activation, antigen presentation (MHC-I upregulation), and leukocyte recruitment (Journal of Neuromuscular Diseases, 2024; Cureus narrative review, 2025) (honda2024contributionofcomplement pages 1-3, honda2024contributionofcomplement pages 8-10, cristofori2025dermatomyositisanarrative pages 2-3). - Dysregulated molecular pathways: IFN-I signaling (IFNAR–JAK1/TYK2–STAT1/2), complement activation and MAC assembly, chemokine axes (e.g., CX3CL1–CX3CR1 in lung), and downstream cytokine networks; in anti-MDA5 DM, immune complexes may engage endosomal TLRs to further induce IFN-α (Rheumatology International, 2024; Current Rheumatology Reports, 2024) (harada2024baricitinibforantimelanoma pages 7-8, musai2024recentupdateson pages 1-2). - Affected cellular processes: endothelial activation and injury, antigen presentation/MHC-I upregulation in myofibers, pDC-driven IFN production, macrophage activation/polarization, keratinocyte apoptosis and interface dermatitis in skin (Children, 2024; Current Rheumatology Reports, 2024) (kobayashi2024advancesinjuvenile pages 13-14, musai2024recentupdateson pages 1-2).
2) Key Molecular Players - Genes/Proteins (HGNC): TRIM33/TIF1-γ, MORC3/NXP2, IFIH1/MDA5, CHD4/Mi-2, SAE1/SAE2; IFNAR1/2, JAK1, TYK2, STAT1; complement C5–C9 (C5b-9). Anti-TIF1-γ/NXP2 associate with malignancy; anti-MDA5 with RP-ILD; anti-Mi-2 with favorable course; anti-SAE with cutaneous-predominant onset (Current Rheumatology Reports, 2024; Seminars in Immunopathology, 2025; Cureus, 2025) (musai2024recentupdateson pages 1-2, ali2025dermatomyositisfocuson pages 1-2, cristofori2025dermatomyositisanarrative pages 2-3). - Chemical Entities (CHEBI): JAK inhibitors (tofacitinib, baricitinib, ruxolitinib), TYK2/JAK1 inhibitor brepocitinib; IVIG—partly effective via complement inhibition (Frontiers in Immunology, 2024; Clin Exp Rheumatology, 2025; Journal of Neuromuscular Diseases, 2024) (ma2024therapeuticefficacyand pages 1-2, paik2025brepocitinibapotent pages 1-2, honda2024contributionofcomplement pages 1-3). - Cell Types (CL): endothelial cells, pDCs, macrophages (CD163+ subsets), CD4+ and CD8+ T cells, B cells/plasma cells, keratinocytes, lung alveolar macrophages (Children, 2024; Current Rheumatology Reports, 2024; Journal of Neuromuscular Diseases, 2024) (kobayashi2024advancesinjuvenile pages 13-14, musai2024recentupdateson pages 1-2, honda2024contributionofcomplement pages 1-3). - Anatomical Locations (UBERON): skin, skeletal muscle, lung (Cureus, 2025; Current Rheumatology Reports, 2024) (cristofori2025dermatomyositisanarrative pages 2-3, musai2024recentupdateson pages 1-2).
3) Biological Processes (GO terms) - Type I interferon signaling pathway (GO:0060337): central DM signature in skin/muscle/blood (Current Rheumatology Reports, 2024) (musai2024recentupdateson pages 1-2). - Complement activation, MAC assembly (GO:0006956): endomysial capillary and sarcolemmal C5b-9 deposition (Journal of Neuromuscular Diseases, 2024) (honda2024contributionofcomplement pages 1-3). - Endothelial cell activation (GO:0042118) and leukocyte chemotaxis (GO:0030595): microangiopathy and perivascular inflammation (Journal of Neuromuscular Diseases, 2024) (honda2024contributionofcomplement pages 1-3). - Antigen processing and presentation of peptide antigen via MHC class I (GO:0002474): myofiber MHC-I overexpression (Cureus, 2025) (cristofori2025dermatomyositisanarrative pages 2-3). - Cellular response to interferon-alpha/beta (GO:0035455/GO:0035456): broad ISG upregulation correlating with activity (Clin Exp Rheumatology, 2025) (paik2025brepocitinibapotent pages 1-2). - NET formation/neutrophil activation (GO:0038061/GO:0042119) and fibrotic pathways including TGF-β signaling in ILD (GO:0007179): implicated particularly in anti-MDA5 RP-ILD (Rheumatology International, 2024) (harada2024baricitinibforantimelanoma pages 7-8).
4) Cellular Components - Endomysial capillary and perimysial vessels: sites of MAC deposition and vasculopathy (Journal of Neuromuscular Diseases, 2024) (honda2024contributionofcomplement pages 1-3). - Sarcolemma: MAC deposition and myofiber injury (Journal of Neuromuscular Diseases, 2024) (honda2024contributionofcomplement pages 1-3). - Dermoepidermal junction: immunoglobulin/complement deposition and interface dermatitis (Cureus, 2025) (cristofori2025dermatomyositisanarrative pages 2-3). - Cytosol/nucleus of myofibers and keratinocytes: intracellular autoantigens (Mi-2/CHD4, TIF1-γ/TRIM33, NXP2/MORC3, SAE1/2) (Current Rheumatology Reports, 2024) (musai2024recentupdateson pages 1-2). - Extracellular space and alveolar compartments: cytokine/chemokine milieu and macrophage activation in ILD (Rheumatology International, 2024) (harada2024baricitinibforantimelanoma pages 7-8).
5) Disease Progression (sequence of events) - Trigger(s): genetic susceptibility and environmental stimuli (e.g., viral RNA sensed by MDA5, UV) initiate innate immune activation with strong IFN-I production by pDCs and other sources (Current Rheumatology Reports, 2024) (musai2024recentupdateson pages 1-2). - Vascular phase: antibody/complement-mediated endothelial injury (MAC deposition) causes capillary dropout and ischemia; clinically, nailfold changes and painful cutaneous ulcers may appear (Journal of Neuromuscular Diseases, 2024; Cureus, 2025) (honda2024contributionofcomplement pages 1-3, cristofori2025dermatomyositisanarrative pages 3-4). - Muscle phase: hypoperfusion and IFN-driven immune activation promote perifascicular atrophy, MHC-I upregulation, and inflammatory infiltrates with macrophages, CD4+ T cells, B cells; proximal weakness ensues (Cureus, 2025) (cristofori2025dermatomyositisanarrative pages 2-3). - Lung involvement: in anti-MDA5 disease, IFN-driven chemokines (CX3CL1) recruit CX3CR1+ M2 macrophages to the lung, fueling ILD and potential fibrosis; RP-ILD may develop with high mortality without aggressive therapy (Rheumatology International, 2024) (harada2024baricitinibforantimelanoma pages 7-8).
6) Phenotypic Manifestations (HP terms) - Proximal muscle weakness (HP:0003701), elevated muscle enzymes, and dysphagia (HP:0002015) reflect myofiber injury and inflammation (Cureus, 2025) (cristofori2025dermatomyositisanarrative pages 2-3). - Heliotrope rash (HP:0001002), Gottron papules (HP:0031408), poikiloderma and photosensitivity (HP:0000992) reflect IFN-driven skin inflammation with interface dermatitis and complement deposition (Cureus, 2025; Seminars in Immunopathology, 2025) (cristofori2025dermatomyositisanarrative pages 2-3, ali2025dermatomyositisfocuson pages 1-2). - Nailfold capillary abnormalities (HP:0030831) reflect microangiopathy (Cureus, 2025) (cristofori2025dermatomyositisanarrative pages 3-4). - Interstitial lung disease (HP:0006530), especially RP-ILD in anti-MDA5 DM, reflects IFN/macrophage-driven lung injury and fibrosis (Rheumatology International, 2024) (harada2024baricitinibforantimelanoma pages 7-8). - Calcinosis cutis (HP:0000987), especially in juvenile/anti-NXP2 disease, indicates chronic tissue damage and dystrophic calcification (Current Rheumatology Reports, 2024) (musai2024recentupdateson pages 1-2).
Evidence items (primary data and statistics; URLs and dates) - Complement microangiopathy and perifascicular atrophy: “deposition of the membrane attack complex (C5b-9) in endomysial capillaries” associates with endothelial/myofiber injury and ischemia; juvenile DM shows capillary loss and small-vessel angiopathy (Journal of Neuromuscular Diseases, Dec 2024; https://doi.org/10.3233/jnd-230168) (honda2024contributionofcomplement pages 1-3, honda2024contributionofcomplement pages 8-10). - IFN score and prognosis in anti-MDA5 DM: A 2023 cohort showed high IFN-I score correlates with disease activity and poor 3‑month survival; patients with IFN‑I score >4.9 had lower 3‑month survival (72.9% vs. 100%; P=0.044) (Frontiers in Immunology, Mar 2023; https://doi.org/10.3389/fimmu.2023.1151695) (rocca2023targetingintracellularpathways pages 3-4). - JAK inhibitors in DM/PM (single‑arm meta-analysis, 7 studies, n=91): mean CDASI improvement −17.67 (95% CI −20.94 to −14.41); MMT +10.31 (95% CI −2.83 to 23.46). Subgroup CDASI reductions: ruxolitinib −20.00, tofacitinib −18.29, baricitinib −11.2. Reported safety included orolabial HSV and two thromboembolic events (Frontiers in Immunology, Mar 2024; https://doi.org/10.3389/fimmu.2024.1382728) (ma2024therapeuticefficacyand pages 1-2). - Anti-MDA5 DM-ILD treated with JAK inhibitors (literature review/case series): pooled survival ~75.9% (predominantly tofacitinib); baricitinib case series (n=3) improved lung opacities and rescued 2/3; notable CMV reactivation risk—close monitoring recommended (Rheumatology International, Mar 2024; https://doi.org/10.1007/s00296-024-05551-2) (harada2024baricitinibforantimelanoma pages 7-8). - JDM JAK inhibitor overview (systematic narrative): Across compiled reports to 2023, muscle improvement in 51/53 (96%); skin improvement in 109/152 (72%); frequent steroid reduction; infections included EBV/CMV/HSV and bacterial/fungal events; hematologic/lipid changes reported (Expert Rev Clin Immunol, Feb 2024; https://doi.org/10.1080/1744666x.2024.2312819) (kim2024updatesonefficacy pages 3-4, kim2024updatesonefficacy pages 13-14). - Rationale for TYK2/JAK1 inhibition: IFN-I signaling via IFNAR engages JAK1/TYK2; selective TYK2/JAK1 blockade (brepocitinib) reduces IFN-α/β, IL-12/23, IFN-γ pathways; large phase 3 trial in DM ongoing (VALOR, NCT0543726) (Clin Exp Rheumatology, Mar 2025; https://doi.org/10.55563/clinexprheumatol/eeglsa) (paik2025brepocitinibapotent pages 1-2).
Expert opinions and analysis - Consensus in recent expert reviews is that DM is best conceptualized as an IFN-driven microangiopathy with autoantibody-defined endotypes that dictate organ risk (malignancy vs. RP-ILD) and may benefit from mechanism-guided therapy, particularly IFN–JAK/STAT pathway inhibition; however, infectious risks (e.g., CMV) and heterogeneity of responses necessitate risk-stratified, monitored use (Current Rheumatology Reports, 2024; Expert Opin Pharmacother, 2024; Rheumatology International, 2024) (musai2024recentupdateson pages 1-2, wallwork2024currentevidencefor pages 1-3, harada2024baricitinibforantimelanoma pages 7-8).
Current applications and real-world implementations - Off-label JAK inhibitor use for refractory cutaneous DM and anti-MDA5 DM-ILD (tofacitinib, baricitinib, ruxolitinib) with documented improvements in CDASI, muscle scores, and ILD survival in observational cohorts; viral surveillance and infection prophylaxis protocols increasingly implemented in high-risk subsets (Frontiers in Immunology, 2024; Rheumatology International, 2024) (ma2024therapeuticefficacyand pages 1-2, harada2024baricitinibforantimelanoma pages 7-8). - IVIG employed to modulate humoral/complement pathways, with mechanistic support that it can block endomysial complement deposition (Journal of Neuromuscular Diseases, 2024) (honda2024contributionofcomplement pages 8-10). - Serology-driven risk management: anti-TIF1-γ/NXP2 prompting intensified cancer screening; anti-MDA5 prompting early, aggressive lung-directed therapy and IFN-pathway targeting (Current Rheumatology Reports, 2024; Cureus, 2025) (musai2024recentupdateson pages 1-2, cristofori2025dermatomyositisanarrative pages 3-4).
Ontology-annotated annotations (HGNC, GO, CL, UBERON, CHEBI, HP) - Genes/Proteins (HGNC): TRIM33 (TIF1-γ), MORC3 (NXP2), IFIH1 (MDA5), CHD4 (Mi-2), SAE1/SAE2; IFNAR1/2, JAK1, TYK2, STAT1; C5–C9 (MAC) (musai2024recentupdateson pages 1-2, honda2024contributionofcomplement pages 1-3). - GO Biological processes: type I interferon signaling (GO:0060337); complement activation (GO:0006956); endothelial activation (GO:0042118); leukocyte chemotaxis (GO:0030595); antigen presentation via MHC-I (GO:0002474); pulmonary fibrosis/TGF-β signaling (GO:0007179) (honda2024contributionofcomplement pages 1-3, musai2024recentupdateson pages 1-2, harada2024baricitinibforantimelanoma pages 7-8). - Cellular components: endomysial capillary, perimysial vessel, sarcolemma, dermoepidermal junction, cytosol/nucleus, extracellular space (honda2024contributionofcomplement pages 1-3, cristofori2025dermatomyositisanarrative pages 2-3). - Cell types (CL): pDCs (CL:0000911), macrophages (CL:0000235), endothelial cells (CL:0000115), CD4+ and CD8+ T cells, B cells/plasma cells, keratinocytes, alveolar macrophages (kobayashi2024advancesinjuvenile pages 13-14, musai2024recentupdateson pages 1-2, honda2024contributionofcomplement pages 1-3). - Anatomical locations (UBERON): skin (UBERON:0002097), skeletal muscle (UBERON:0002090), lung (UBERON:0002048) (cristofori2025dermatomyositisanarrative pages 2-3, musai2024recentupdateson pages 1-2). - Chemical entities (CHEBI): tofacitinib, baricitinib, ruxolitinib, brepocitinib, intravenous immunoglobulin (ma2024therapeuticefficacyand pages 1-2, paik2025brepocitinibapotent pages 1-2, honda2024contributionofcomplement pages 1-3). - Phenotypes (HP): proximal muscle weakness (HP:0003701), heliotrope rash (HP:0001002), Gottron papules (HP:0031408), photosensitivity (HP:0000992), dysphagia (HP:0002015), interstitial lung disease (HP:0006530), calcinosis cutis (HP:0000987), nailfold capillary abnormalities (HP:0030831) (ali2025dermatomyositisfocuson pages 1-2, cristofori2025dermatomyositisanarrative pages 2-3, harada2024baricitinibforantimelanoma pages 7-8).
Direct quotes (selected) - “deposition of the membrane attack complex (C5b-9) in endomysial capillaries” (Journal of Neuromuscular Diseases, 2024; https://doi.org/10.3233/jnd-230168) (honda2024contributionofcomplement pages 1-3). - “type I interferon gene transcription scores in blood correlate strongly with DM disease activity” and “decrease significantly with immunomodulatory therapy” (Clin Exp Rheumatology, 2025; https://doi.org/10.55563/clinexprheumatol/eeglsa) (paik2025brepocitinibapotent pages 1-2). - In anti-MDA5 DM-ILD treated with JAK inhibitors, “the survival rate was 75.9%” in pooled literature, and “the incidence of CMV reactivation appeared to be high” (Rheumatology International, 2024; https://doi.org/10.1007/s00296-024-05551-2) (harada2024baricitinibforantimelanoma pages 7-8).
Recent developments (2023–2024 priority) - IFN-I score as prognostic biomarker in anti-MDA5 DM: high baseline IFN-I score associated with higher disease activity and lower 3‑month survival (72.9% vs 100%) (Frontiers in Immunology, Mar 2023; https://doi.org/10.3389/fimmu.2023.1151695) (rocca2023targetingintracellularpathways pages 3-4). - JAK inhibitors meta-analysis (Mar 2024) demonstrates clinically meaningful cutaneous improvement (CDASI −17.67) and muscle strength gains; safety acceptable but vigilance for thromboembolism and infection required (Frontiers in Immunology, Mar 2024; https://doi.org/10.3389/fimmu.2024.1382728) (ma2024therapeuticefficacyand pages 1-2). - Anti-MDA5 DM-ILD case series/review (Mar 2024) supports JAK inhibition in RP-ILD with survival ~75.9% and highlights CMV risk and need for monitoring (Rheumatology International, Mar 2024; https://doi.org/10.1007/s00296-024-05551-2) (harada2024baricitinibforantimelanoma pages 7-8). - Expert therapeutic overviews (Aug 2024) outline growing evidence base and active randomized trials of JAK/TYK2 inhibitors in adult and juvenile DM (Expert Opin Pharmacother, Aug 2024; https://doi.org/10.1080/14656566.2024.2392021) (wallwork2024currentevidencefor pages 1-3).
Applications, implementations, and safety - Implementation: off-label JAK inhibitor regimens (e.g., tofacitinib 5–10 mg BID; baricitinib 2–4 mg daily) with multi-drug background therapy, serial IFN score and viral surveillance (CMV/EBV/BK) in high-risk anti-MDA5 subsets; IVIG used to curb complement-mediated injury (Frontiers in Immunology, 2024; Journal of Neuromuscular Diseases, 2024) (ma2024therapeuticefficacyand pages 1-2, honda2024contributionofcomplement pages 8-10). - Safety: infections (HSV, CMV, bacterial/fungal), cytopenias, lipids/weight changes; in anti-MDA5 DM-ILD, CMV reactivation is common enough to warrant pre-emptive monitoring/antivirals and temporary drug holds (Expert Rev Clin Immunol, 2024; Rheumatology International, 2024) (kim2024updatesonefficacy pages 13-14, harada2024baricitinibforantimelanoma pages 7-8).
Structured artifacts (ontology-mapped summary) | Category | Entity (preferred name) | Ontology tag | Mechanistic role in DM | Phenotype/clinical association | Key evidence | Notes | |---|---|---|---|---|---|---| | Pathway | Type I interferon pathway (IFNA/IFNB → IFNAR1/2 → JAK1/TYK2 → STAT1) | IFNA/IFNB, IFNAR1, IFNAR2, JAK1, TYK2, STAT1 (HGNC); GO:0060337 (type I interferon signaling) | Drives a dominant transcriptional signature (ISGs) in skin and muscle; promotes MHC-I upregulation and immune cell recruitment | Correlates with disease activity, anti‑MDA5 severity, and poor prognosis in RP‑ILD | (musai2024recentupdateson pages 1-2, kim2025juveniledermatomyositisupdates pages 1-2, cristofori2025dermatomyositisanarrative pages 2-3) | Therapeutic target of JAK inhibitors; measurable IFN score biomarker | | Complement | Complement membrane attack complex (C5b-9 / MAC) | C5 (HGNC); GO:0006956 (complement activation) ; Cellular component: extracellular space / endomysial capillary | Deposition on endomysial capillaries and sarcolemma causing endothelial/myofiber injury and microangiopathy | Associated with perifascicular atrophy, capillary loss, and juvenile DM vascular pathology | (honda2024contributionofcomplement pages 1-3, honda2024contributionofcomplement pages 8-10, cristofori2025dermatomyositisanarrative pages 3-4) | IVIG can block complement deposition; complement implicated in antibody-mediated endothelial damage | | Cell type | Plasmacytoid dendritic cell (pDC) | CL:0000911 (pDC) ; GO:0034340 (type I interferon production) | Main source of type I IFNs in affected tissues; present in inflamed muscle and skin, amplifies IFN signature | Contributes to local inflammation and IFN-driven tissue damage | (kobayashi2024advancesinjuvenile pages 13-14, musai2024recentupdateson pages 1-2, honda2024contributionofcomplement pages 1-3) | pDCs link innate viral-sensing to autoimmunity in DM | | Cell type | Endothelial cell | CL:0000115 (endothelial cell); GO:0042118 (endothelial cell activation) ; Cellular component: endomysial capillary | Target of autoantibody- and complement-mediated injury leading to microangiopathy and ischemia | Perivascular inflammation, capillary dropout, microhemorrhages; drives perifascicular changes | (honda2024contributionofcomplement pages 1-3, honda2024contributionofcomplement pages 8-10) | Endothelial activation biomarkers associate with disease activity | | Tissue/cell | Skeletal muscle fiber (myofiber) | UBERON:0002090 (skeletal muscle) ; Cellular component: sarcolemma, cytosol, nucleus | Display MHC‑I upregulation, atrophy/necrosis from hypoperfusion and immune attack; regenerative changes | Proximal symmetric weakness, elevated CK, perifascicular atrophy on biopsy | (cristofori2025dermatomyositisanarrative pages 2-3, musai2024recentupdateson pages 1-2) | Autoantibody entry into myofibers may disrupt intracellular targets | | Cell type | Macrophage (incl. CD163+ subsets) | CD163 (HGNC); CL:0000235 (macrophage) | Produce cytokines, present antigen, participate in interferon-driven inflammation and tissue remodeling | Associated with perimysial/perifascicular infiltration; implicated in anti‑MDA5 lung pathology | (musai2024recentupdateson pages 1-2, honda2024contributionofcomplement pages 8-10) | Macrophage polarization (M1/M2) influences damage vs repair | | Cell type | T cell (CD4+, CD8+) | CD4, CD8A (HGNC); CL terms for T cell subsets | CD4+ perivascular infiltrates; CD8+ implicated in cytotoxic responses and paraneoplastic links | Lymphocytic infiltration on muscle biopsy; CD8+ associated with some cancer‑linked phenotypes | (cristofori2025dermatomyositisanarrative pages 2-3, musai2024recentupdateson pages 1-2) | T cell roles vary by autoantibody-defined subtype | | Cell type | B cell / plasma cell | CD19, CD20 (HGNC); CL:0000236 (B cell) | Source of myositis-specific autoantibodies; antigen presentation and local antibody production | Autoantibodies stratify phenotypes (malignancy risk, ILD risk) and guide therapy (rituximab) | (musai2024recentupdateson pages 1-2, kim2025juveniledermatomyositisupdates pages 1-2) | B‑cell depletion and emerging CD19 CAR‑T approaches under investigation | | Cell type | Keratinocyte | CL:0000134 (epidermal keratinocyte) ; Cellular component: dermoepidermal junction | Responds to IFN signaling and shows immune complex / complement deposition → apoptosis and rash | Gottron papules, heliotrope rash, poikiloderma; cutaneous ulceration in severe/anti‑MDA5 cases | (cristofori2025dermatomyositisanarrative pages 2-3, ali2025dermatomyositisfocuson pages 1-2) | Skin changes mirror muscle IFN-driven pathology | | Cell type | Lung alveolar macrophage | CL:0000235 (macrophage); UBERON lung alveolus | Participate in IFN/cytokine networks and macrophage activation contributing to ILD | Central in anti‑MDA5 RP‑ILD pathogenesis and respiratory failure | (kim2025juveniledermatomyositisupdates pages 1-2, musai2024recentupdateson pages 1-2) | Therapies targeting IFN/JAK may modulate pulmonary macrophage activation | | Autoantigen / autoantibody | TRIM33 / TIF1-γ | TRIM33 (HGNC) / anti‑TIF1-γ MSA | Autoantigen targeted by autoantibodies; potential paraneoplastic antigen linking tumor neoantigens to autoimmunity | Strongly associated with cancer‑associated DM and specific cutaneous phenotypes | (cristofori2025dermatomyositisanarrative pages 2-3, musai2024recentupdateson pages 1-2) | TIF1-γ serology used for cancer risk stratification | | Autoantigen / autoantibody | NXP2 | NXP2 (MORC3?) — NXP2 (gene) (HGNC) | Nuclear matrix protein targeted by autoantibodies; associated with distinct muscle/skin pathology | Linked to adult cancer risk, calcinosis, severe weakness and dysphagia | (cristofori2025dermatomyositisanarrative pages 2-3, musai2024recentupdateson pages 1-2) | Phenotype associations vary by age group | | Autoantigen / autoantibody | MDA5 / IFIH1 | IFIH1 (HGNC) / anti‑MDA5 MSA | Viral RNA sensor; autoantibodies linked to IFN overactivation and macrophage/monocyte dynamics | Clinically amyopathic DM, high risk of rapidly progressive ILD (RP‑ILD) and poor pulmonary prognosis | (kim2025juveniledermatomyositisupdates pages 1-2, musai2024recentupdateson pages 1-2) | Geographic/seasonal patterns noted; anti‑MDA5 titer correlates with severity | | Autoantigen / autoantibody | Mi‑2 / CHD4 | CHD4 (HGNC) / anti‑Mi‑2 MSA | Autoantibody associated with classic DM histology; less oncologic risk | Favorable prognosis, characteristic cutaneous findings | (musai2024recentupdateson pages 1-2, ali2025dermatomyositisfocuson pages 1-2) | Mi‑2 subtype historically linked to good treatment response | | Autoantigen / autoantibody | SAE1 / SAE2 | SAE1, SAE2 (HGNC) / anti‑SAE MSA | Autoantibody linked to cutaneous‑predominant onset and systemic features | Florid skin disease, delayed muscle weakness, possible increased cancer risk | (ali2025dermatomyositisfocuson pages 1-2, musai2024recentupdateson pages 1-2) | SAE serology marks a distinct clinical trajectory | | Organ site | Skin | UBERON:0002097 (skin) ; Cellular component: dermoepidermal junction | Primary target of IFN-driven inflammation, immune complex/complement deposition | Pathognomonic rashes (Gottron, heliotrope), ulcers, photosensitivity; reflects systemic disease activity | (cristofori2025dermatomyositisanarrative pages 2-3, ali2025dermatomyositisfocuson pages 1-2) | Skin biopsies and capillaroscopy provide diagnostic/prognostic clues | | Organ site | Skeletal muscle | UBERON:0002090 (skeletal muscle) ; Cellular component: endomysial capillary, sarcolemma | Site of microangiopathy, myofiber ischemia/necrosis, MHC‑I upregulation and immune infiltration | Proximal muscle weakness, elevated muscle enzymes, biopsy changes including perifascicular atrophy | (honda2024contributionofcomplement pages 1-3, musai2024recentupdateson pages 1-2) | Muscle MRI and biopsy remain key diagnostic tools | | Organ site | Lung | UBERON:0002048 (lung) ; GO:0035966 (pulmonary fibrosis) | Target of inflammatory and fibrotic sequelae driven by IFN/cytokines and macrophage activation | Interstitial lung disease (ILD), rapidly progressive ILD in anti‑MDA5 patients | (kim2025juveniledermatomyositisupdates pages 1-2, musai2024recentupdateson pages 1-2) | ILD is a major determinant of mortality in specific DM subtypes | | Therapeutic | Tofacitinib (JAK1/2/3 inhibitor) | CHEBI:tofacitinib (drug) ; acts on JAK/STAT pathway | Inhibits downstream signaling of type I IFN and other cytokines to reduce inflammation | Improves cutaneous disease and some muscle outcomes in refractory DM (case series/meta-analyses) | (musai2024recentupdateson pages 1-2, kim2025juveniledermatomyositisupdates pages 1-2, ali2025dermatomyositisfocuson pages 1-2) | Off‑label use reported; safety profile includes infection risk | | Therapeutic | Baricitinib (JAK1/2 inhibitor) | CHEBI:baricitinib | JAK inhibition reducing IFN signaling; reported benefit in anti‑MDA5 ILD case series | Case series report lung improvement and survival benefit in some cohorts | (kim2025juveniledermatomyositisupdates pages 1-2, musai2024recentupdateson pages 1-2, honda2024contributionofcomplement pages 8-10) | Monitoring for opportunistic infections and CMV reactivation advised | | Therapeutic | Ruxolitinib (JAK1/2 inhibitor) | CHEBI:ruxolitinib | JAK inhibition, targets IFN and other cytokine signaling | Case reports/series show cutaneous and systemic benefit | (musai2024recentupdateson pages 1-2, ali2025dermatomyositisfocuson pages 1-2) | Topical and systemic formulations have been used in refractory cases | | Therapeutic | Brepocitinib (TYK2/JAK1 inhibitor) | CHEBI:brepocitinib | Inhibits TYK2/JAK1 to reduce IFN‑α/β and other cytokine signaling; under phase 3 study in DM | Rationale for use based on IFN biology; large trials ongoing (VALOR) | (honda2024contributionofcomplement pages 8-10, musai2024recentupdateson pages 1-2) | Potential to target multiple pathogenic cytokines with oral therapy | | Therapeutic | Intravenous immunoglobulin (IVIG) | CHEBI:immunoglobulin (IVIG) | Modulates Fc receptors, neutralizes autoantibodies, and can inhibit complement deposition | Effective in refractory cutaneous and muscle disease; may reduce complement-mediated injury | (honda2024contributionofcomplement pages 1-3, honda2024contributionofcomplement pages 8-10) | Mechanisms include complement inhibition and immune modulation |
Table: Concise knowledge‑base table mapping key entities (pathways, cells, autoantigens, organs, therapies) to ontology tags, mechanistic roles, clinical associations, and supporting evidence (context IDs). Useful for structured disease annotation and rapid reference.
Evidence catalog (with PMIDs/DOIs provided via URLs where available) - Complement, microangiopathy, perifascicular atrophy and IFN biomarkers in DM: Journal of Neuromuscular Diseases, Dec 2024; https://doi.org/10.3233/jnd-230168 (honda2024contributionofcomplement pages 1-3, honda2024contributionofcomplement pages 8-10). - IFN-driven pathogenesis and autoantibody-defined endotypes: Current Rheumatology Reports, Sep 2024; https://doi.org/10.1007/s11926-024-01164-7 (musai2024recentupdateson pages 1-2). - pDCs and IFN signature in pediatric disease; vasculopathy: Children, Aug 2024; https://doi.org/10.3390/children11091046 (kobayashi2024advancesinjuvenile pages 13-14). - Anti-MDA5 DM-ILD pathogenesis and JAK inhibition outcomes and risks: Rheumatology International, Mar 2024; https://doi.org/10.1007/s00296-024-05551-2 (harada2024baricitinibforantimelanoma pages 7-8). - JAK inhibitor meta-analysis (DM/PM): Frontiers in Immunology, Mar 2024; https://doi.org/10.3389/fimmu.2024.1382728 (ma2024therapeuticefficacyand pages 1-2). - JDM JAK inhibitor outcomes and safety: Expert Rev Clin Immunol, Feb 2024; https://doi.org/10.1080/1744666x.2024.2312819 (kim2024updatesonefficacy pages 3-4, kim2024updatesonefficacy pages 13-14). - TYK2/JAK1 rationale (brepocitinib) and IFN score–activity correlations: Clin Exp Rheumatology, Mar 2025; https://doi.org/10.55563/clinexprheumatol/eeglsa (paik2025brepocitinibapotent pages 1-2). - Integrative clinical narrative for DM skin-muscle-malignancy linkages: Cureus, Jul 2025; https://doi.org/10.7759/cureus.88601 (cristofori2025dermatomyositisanarrative pages 2-3, cristofori2025dermatomyositisanarrative pages 3-4).
Limitations and open questions - Most interventional evidence remains observational; high-quality randomized, controlled trials of JAK/TYK2 inhibitors and other targeted agents are ongoing. Infection risks, optimal dosing, biomarkers for selection/monitoring (e.g., IFN score cutoffs), and long-term malignancy outcomes by MSA subtype remain active areas of research (Expert Opin Pharmacother, 2024; Clin Exp Rheumatology, 2025) (wallwork2024currentevidencefor pages 1-3, paik2025brepocitinibapotent pages 1-2).
References
(honda2024contributionofcomplement pages 1-3): Masaya Honda, Fumitaka Shimizu, Ryota Sato, and Masayuki Nakamori. Contribution of complement, microangiopathy and inflammation in idiopathic inflammatory myopathies. Journal of Neuromuscular Diseases, 11:5-16, Dec 2024. URL: https://doi.org/10.3233/jnd-230168, doi:10.3233/jnd-230168. This article has 6 citations and is from a peer-reviewed journal.
(honda2024contributionofcomplement pages 8-10): Masaya Honda, Fumitaka Shimizu, Ryota Sato, and Masayuki Nakamori. Contribution of complement, microangiopathy and inflammation in idiopathic inflammatory myopathies. Journal of Neuromuscular Diseases, 11:5-16, Dec 2024. URL: https://doi.org/10.3233/jnd-230168, doi:10.3233/jnd-230168. This article has 6 citations and is from a peer-reviewed journal.
(cristofori2025dermatomyositisanarrative pages 2-3): Maria Cristofori, José C González-Rodríguez, Emmanuel E Cortés - Marín, Adipp Sallón, and Jairo Sandoval. Dermatomyositis: a narrative review of skin as a window to muscle and malignancy. Cureus, Jul 2025. URL: https://doi.org/10.7759/cureus.88601, doi:10.7759/cureus.88601. This article has 1 citations and is from a poor quality or predatory journal.
(musai2024recentupdateson pages 1-2): Jon Musai, Andrew L. Mammen, and Iago Pinal-Fernandez. Recent updates on the pathogenesis of inflammatory myopathies. Current Rheumatology Reports, 26:421-430, Sep 2024. URL: https://doi.org/10.1007/s11926-024-01164-7, doi:10.1007/s11926-024-01164-7. This article has 15 citations and is from a peer-reviewed journal.
(kobayashi2024advancesinjuvenile pages 13-14): Ichiro Kobayashi. Advances in juvenile dermatomyositis: pathophysiology, diagnosis, treatment and interstitial lung diseases—a narrative review. Children, 11:1046, Aug 2024. URL: https://doi.org/10.3390/children11091046, doi:10.3390/children11091046. This article has 7 citations and is from a poor quality or predatory journal.
(cristofori2025dermatomyositisanarrative pages 3-4): Maria Cristofori, José C González-Rodríguez, Emmanuel E Cortés - Marín, Adipp Sallón, and Jairo Sandoval. Dermatomyositis: a narrative review of skin as a window to muscle and malignancy. Cureus, Jul 2025. URL: https://doi.org/10.7759/cureus.88601, doi:10.7759/cureus.88601. This article has 1 citations and is from a poor quality or predatory journal.
(ali2025dermatomyositisfocuson pages 1-2): Hammad Ali, Aretha On, Enze Xing, Catherine Z Shen, and V. Werth. Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment. Seminars in Immunopathology, Aug 2025. URL: https://doi.org/10.1007/s00281-025-01054-9, doi:10.1007/s00281-025-01054-9. This article has 2 citations and is from a domain leading peer-reviewed journal.
(ma2024therapeuticefficacyand pages 1-2): Chenhang Ma, Mengyao Liu, Yang Cheng, Xinchang Wang, Yu Zhao, Kailu Wang, and Weijie Wang. Therapeutic efficacy and safety of jak inhibitors in treating polymyositis/dermatomyositis: a single-arm systemic meta-analysis. Frontiers in Immunology, Mar 2024. URL: https://doi.org/10.3389/fimmu.2024.1382728, doi:10.3389/fimmu.2024.1382728. This article has 15 citations and is from a peer-reviewed journal.
(harada2024baricitinibforantimelanoma pages 7-8): Hiroaki Harada, Hirofumi Shoda, Haruka Tsuchiya, Makoto Misaki, Takayuki Sawada, and Keishi Fujio. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on janus kinase inhibitors for the disease. Rheumatology International, 44:961-971, Mar 2024. URL: https://doi.org/10.1007/s00296-024-05551-2, doi:10.1007/s00296-024-05551-2. This article has 19 citations and is from a peer-reviewed journal.
(wallwork2024currentevidencefor pages 1-3): Rachel S. Wallwork, Julie J. Paik, and Hanna Kim. Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons. Expert Opinion on Pharmacotherapy, 25:1625-1645, Aug 2024. URL: https://doi.org/10.1080/14656566.2024.2392021, doi:10.1080/14656566.2024.2392021. This article has 7 citations and is from a peer-reviewed journal.
(paik2025brepocitinibapotent pages 1-2): Julie J. Paik, Jiri Vencovský, Christina Charles-Schoeman, Grace C. Wright, Ruth Ann Vleugels, Alexandra S. Goriounova, Jr Paul N. Mudd, and Rohit Aggarwal. Brepocitinib, a potent and selective tyk2/jak1 inhibitor: scientific and clinical rationale for dermatomyositis. Clinical and experimental rheumatology, Mar 2025. URL: https://doi.org/10.55563/clinexprheumatol/eeglsa, doi:10.55563/clinexprheumatol/eeglsa. This article has 12 citations and is from a peer-reviewed journal.
(rocca2023targetingintracellularpathways pages 3-4): Gaetano La Rocca, Francesco Ferro, Chiara Baldini, Alessandro Libra, Domenico Sambataro, Michele Colaci, Lorenzo Malatino, Stefano Palmucci, Carlo Vancheri, and Gianluca Sambataro. Targeting intracellular pathways in idiopathic inflammatory myopathies: a narrative review. Frontiers in Medicine, Mar 2023. URL: https://doi.org/10.3389/fmed.2023.1158768, doi:10.3389/fmed.2023.1158768. This article has 17 citations and is from a poor quality or predatory journal.
(kim2024updatesonefficacy pages 3-4): Hanna Kim. Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis. Expert Review of Clinical Immunology, 20:589-602, Feb 2024. URL: https://doi.org/10.1080/1744666x.2024.2312819, doi:10.1080/1744666x.2024.2312819. This article has 9 citations and is from a peer-reviewed journal.
(kim2024updatesonefficacy pages 13-14): Hanna Kim. Updates on efficacy and safety janus kinase inhibitors in juvenile dermatomyositis. Expert Review of Clinical Immunology, 20:589-602, Feb 2024. URL: https://doi.org/10.1080/1744666x.2024.2312819, doi:10.1080/1744666x.2024.2312819. This article has 9 citations and is from a peer-reviewed journal.
(kim2025juveniledermatomyositisupdates pages 1-2): Hanna Kim. Juvenile dermatomyositis: updates in pathogenesis and biomarkers, current treatment, and emerging targeted therapies. Paediatric Drugs, 27:57-72, Oct 2025. URL: https://doi.org/10.1007/s40272-024-00658-2, doi:10.1007/s40272-024-00658-2. This article has 8 citations and is from a peer-reviewed journal.